CAR T-Cell Immunotherapy in Minority Patients with Lymphoma.

MLA

Ghilardi, Guido, et al. “CAR T-Cell Immunotherapy in Minority Patients with Lymphoma.” NEJM Evidence, vol. 3, no. 4, Apr. 2024, pp. 1–14. EBSCOhost, https://doi.org/10.1056/EVIDoa2300213.

APA

Ghilardi, G., Williamson, S., Pajarillo, R., Paruzzo, L., Chen, L., Grady, C., Doucette, A., Nemecek, E., Gabrielli, G., Barta, S. K., Svoboda, J., Chong, E. A., Yelton, R., Nasta, S. D., Landsburg, D. J., Ugwuanyi, O., Chen, A. I., Schachter, L., White, G., & Ballard, H. J. (2024). CAR T-Cell Immunotherapy in Minority Patients with Lymphoma. NEJM Evidence, 3(4), 1–14. https://doi.org/10.1056/EVIDoa2300213

Chicago

Ghilardi, Guido, Staci Williamson, Raymone Pajarillo, Luca Paruzzo, Linhui Chen, Connor Grady, Abigail Doucette, et al. 2024. “CAR T-Cell Immunotherapy in Minority Patients with Lymphoma.” NEJM Evidence 3 (4): 1–14. doi:10.1056/EVIDoa2300213.